Molecular mechanism of abnormal aggregation of α-synuclein

Chinese Science Bulletin

Volumn 52, Issue 2, 2007, Pages 159-164

  Hu, HongYu ^a   Lin, XiaoJing ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

synuclein; Aggregation; Molecular mechanism; Parkinson's disease

Indexed keywords

EID: 33847649538     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-007-0037-z     Document Type: Article

References (32)

1. Maroteaux L, Campanelli, J T, Scheller R H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 1988, 8: 2804-2815
2. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA, 1993, 90: 11282-11286
3. Jakes R, Spillantini M G, Goedert M. Identification of two distinct synucleins from human brain. FEBS lett, 1994, 345: 27-32
4. Polymeropoulos M H, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276: 2045-2047
5. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genet, 1998, 18: 106-108
6. Spillantini M G, Schmidt M L, Lee V M, et al. Alpha-synuclein in Lewy bodies. Nature, 1997, 388: 839-840
7. Conway K A, Harper J D, Lansbury P T Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 2000, 39: 2552-2563
8. Uversky V N, Fink A L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta, 2004, 1698: 131-153
9. Hu H Y. Abnormal protein aggregation and neurodegenerative diseases. Chin Sci Bull, 2001, 46(1): 1-3
10. El-Agnaf O M A, Jakes R, Curran M D, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett, 1998, 440: 71-75
11. Li H T, Du H N, Tang L, et al. Structural transformation and aggregation of human α-synuclein in trifluoroethanol: NAC sequence is essential and β-sheet formation is prerequisite to aggregation. Biopolymers, 2002, 64: 221-226
12. El-Agnaf O M A, Bodles A M, Guthrie D J S, et al. The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur J Biochem, 1998, 258: 157-163
13. Biere A L, Wood S J, Wypych J, et al. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem, 2000, 275: 34574-34579
14. Du H N, Tang L, Luo X Y, et al. A peptide motif consisting of glycine, alanine and valine is required for fibrillization and cytotoxicity of human α-synuclein. Biochemistry, 2003, 42: 8870-8878
15. Harper J D, Lansbury P T Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem, 1997, 66: 385-407
16. Ji L N, Du H N, Zhang F, et al. An unstructured region is required by GAV homologue for the fibrillization of host proteins. Protein J, 2005, 24: 209-218
17. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci, 2002, 22: 2780-2791
18. Li H T, Lin D H, Luo X Y, et al. Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein: Implication for dopaminergic neurodegeneration. FEBS J, 2005, 272: 3661-3672
19. Goldberg M S, Lansbury P T Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol, 2000, 2: E115-E119
20. El-Agnaf O M A, Paleologou K E, Greer B, et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J, 2004, 18: 1315-1318
21. Du H N, Li H T, Zhang, F, et al. Acceleration of α-synuclein aggregation by homologous peptides. FEBS Lett, 2006, 580: 3657-3664
22. Hu H Y, Li Q, Cheng H Q, et al. β-sheet structure formation of proteins in solid state as revealed by circular dichroism spectroscopy. Biopolymers, 2001, 62: 15-21
23. McPhie P. Circular dichroism studies on proteins in films and in solution: Estimation of secondary structure by g-factor analysis. Anal Biochem, 2001, 293: 109-119
24. McPhie P. CD studies on films of amyloid proteins and polypeptides: Quantitative g-factor analysis indicates a common folding motif. Biopolymers, 2004, 75: 140-147
25. Lin X J, Zhang F, Xie Y Y, et al. Secondary structural formation of α-synuclein amyloids as revealed by g-factor of solid-state circular dichroism. Biopolymers, 2006, 83: 226-232
26. Lee H J, Lee S J. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem, 2002, 277: 48976-48973
27. Li H T, Lin X J, Xie Y Y. The early events of α-synuclein oligomerization revealed by photo-induced cross-linking. Protein Pept Lett, 2006, 13: 385-390
28. Apetri M M, Maiti N C, Zagorski M G, et al. Secondary structure of alpha-synuclein oligomers: Characterization by raman and atomic force microscopy. J Mol Biol, 2006, 355: 63-71
29. Dusa A, Kaylor J, Edridge S, et al. Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry, 2006, 45: 2752-2760
30. Makin O S, Serpell L C. Structures for amyloid fibrils. FEBS J, 2005, 272: 5950-5961
31. Miake H, Mizusawa H, Iwatsubo T, et al. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem, 2002, 277: 19213-19219
32. Tang L, Li H T, Du H N, et al. Study of the disassembly-assembly process of α-synuclein fibrils by in situ atomic force microscopy. Micron, 2006, 37: 675-679